Literature DB >> 3038696

Expression and secretion in yeast of a 400-kDa envelope glycoprotein derived from Epstein-Barr virus.

L D Schultz, J Tanner, K J Hofmann, E A Emini, J H Condra, R E Jones, E Kieff, R W Ellis.   

Abstract

The major envelope glycoprotein (gp350) of Epstein-Barr virus has been expressed and secreted in the yeast Saccharomyces cerevisiae as a 400-kDa glycoprotein. This is the first example of the secretion of such a large, heavily glycosylated heterologous protein in yeast. Since gp350 proved highly toxic to S. cerevisiae, initial cellular growth required repression of the expression of gp350. Using temperature- or galactose-inducible promoters, cells could be grown and the expression of gp350 then induced. After induction, the glycoprotein accumulated both intracellularly as well as in the culture medium. Only the most heavily glycosylated form was secreted, suggesting a role for N-linked glycans in directing secretion. The extent of O-linked glycosylation of the yeast-derived protein was similar to that of the mature viral gp350. N-linked glycosylation varied slightly depending upon culture conditions and host strain used and was more extensive than that associated with the mature viral gp350. Although there is no evidence that more than a single mRNA for the glycoprotein was expressed from the recombinant plasmid, variously sized glycoproteins accumulated in yeast at early stages after induction, probably reflecting intermediates in glycosylation. The yeast-derived glycoproteins reacted with animal and human polyclonal antibodies to gp350 as well as with a neutralizing murine monoclonal antibody to gp350, suggesting that this glycoprotein retains several epitopes of the native glycoprotein.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3038696     DOI: 10.1016/0378-1119(87)90353-2

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  6 in total

Review 1.  Control of viral disease: the development of Epstein-Barr virus vaccines.

Authors:  A J Morgan
Journal:  Springer Semin Immunopathol       Date:  1991

2.  Growth rate influences MF alpha 1 promoter activity in MAT alpha Saccharomyces cerevisiae.

Authors:  N Kirk; P W Piper
Journal:  Appl Microbiol Biotechnol       Date:  1994-11       Impact factor: 4.813

3.  Construction of the complete rat fatty acid synthase cDNA and its expression in Saccharomyces cerevisiae.

Authors:  R Kupfer; F Beiche; M Schweizer
Journal:  Curr Genet       Date:  1996-02       Impact factor: 3.886

4.  Cloning and analysis of the Saccharomyces cerevisiae MNN9 and MNN1 genes required for complex glycosylation of secreted proteins.

Authors:  C L Yip; S K Welch; F Klebl; T Gilbert; P Seidel; F J Grant; P J O'Hara; V L MacKay
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-29       Impact factor: 11.205

5.  Abnormal growth induced by expression of HBsAg in the secretion pathway of S. cerevisiae pep4 mutants.

Authors:  D C Chen; L T Chuang; W P Chen; T T Kuo
Journal:  Curr Genet       Date:  1995-02       Impact factor: 3.886

6.  Expression of the human blood coagulation protein factor XIIIa in Saccharomyces cerevisiae: dependence of the expression levels from host-vector systems and medium conditions.

Authors:  M Bröker; O Bäuml; A Göttig; J Ochs; M Bodenbenner; E Amann
Journal:  Appl Microbiol Biotechnol       Date:  1991-03       Impact factor: 4.813

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.